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A B S T R A C T  
Objectives: To find out the prevalence of portal hypertensive gastropathy among patients of viral cirrhosis undergoing 
endoscopy and to determine its association with esophageal varices in patients of cirrhosis.   
Patients and Methods: This cross-sectional study was conducted at Medical Unit, Jinnah Hospital Lahore from 3rd 
September 2016 to 2nd January 2017. A total of 120 patients with liver cirrhosis fulfilling the inclusion criteria were 
approached and an informed consent was taken before enrolling in the study. All patients underwent upper 
gastrointestinal tract endoscopy by consultant endoscopist. Data was entered on SPSS Version 17   for further analysis.  
Results: Out of 120 patients, 43% were males and 57% were females. The mean age of participants was 39.71+11.6 
SD years. Portal hypertensive gastropathy was present in 12.5% patients and esophageal varices in 42.5% patients. 
HBsAg and anti-HCV was positive in 60.8% and 45.8% patients respectively. Non-significant association was found 
between portal hypertensive gastropathy and esophageal varices (p-value 0.364). 
Conclusion: Emergence of portal hypertensive gastropathy and Esophageal varices was noticed among patients of viral 
cirrhosis. However non-significant association was found between portal hypertensive gastropathy and esophageal 
varices.  
Keywords: Cirrhosis, Esophageal varices, Portal hypertensive gastropathy 
Author`s Contribution 
1Conception, Synthesis and Planning of the 
research-2-4Active participation in active 
methodology, 5Interpretation and discussion, 
6,7Analysis  
Address of Correspondence 
Muhammad Salman walayt 
Pastel_6@live.com 
Article info. 
Received: Mar 21, 2017 
Accepted: May 25, 2017 
 
Cite this article: Aslam MS,Nasir KM, Hussain H, Altaf MO, Farrukjh S, Saeed M. Association of Portal 
Hypertensive Gastropathy with Esophageal Varices among Patients of Viral Cirrhosis. JIMDC. 2017; 
6(2):72-76. 
Funding Source: Nil 
Conflict of Interest: Nil 
I n t r o d u c t i o n  
 
Cirrhosis being the decompensated disease, is 
responsible for high rate of morbidity and mortality. The 
quality of life and survival of patients with cirrhosis can be 
improved by appropriate and timely management. More 
than 25,000 deaths and 373,000 hospital discharges in 
the United States in 1998 have been reported according 
to a report from The National Centre for Health.1 Portal 
hypertension leads to an increase in blood flow in veins of 
the lower esophagus and stomach. These veins are not 
designed for the higher pressure, and thus they begin to 
expand, resulting in varices. Once varices develop, they 
can remain stable, increase in size (if the liver disease 
worsens), or decrease in size (if the liver disease 
improves). 
Portal hypertension is a progressive complication of 
cirrhosis. Therefore, management of the patient with 
cirrhosis and portal hypertensive gastrointestinal bleeding 
depends on the phase of portal hypertension,  
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Practice guidelines for the diagnosis and treatment of 
gastroesophageal variceal haemorrhage, endorsed by the 
American Association for the Study of Liver Diseases 
(AASLD), American College of Gastroenterology (ACG), 
American Gastroenterological Association (AGA), and 
American Society for Gastrointestinal Endoscopy (ASGE), 
were published in 1997.2   Esophageal varices are a 
common complication of advanced cirrhosis that results 
directly from portal hypertension. In people with cirrhosis, 
varices develop when blood flow through the liver is 
obstructed by scarring, increasing the pressure inside the 
portal vein. 
The strongest predictor for the development of varices in 
those with cirrhosis who have no varices at the time of 
initial endoscopic screening is Hepatic vein pressure 
gradient (HVPG) >10 mmHg.3 Patients with an HVPG >20 
mmHg (measured within 24 hours of variceal 
haemorrhage) have been identified as being at a higher 
risk for early rebleed (recurrent bleeding within the first 
week of admission) or failure to control bleeding and a 
higher 1-year mortality compared to those with lower 
pressure.4 Esophagogastroduodenoscopy (EGD) is a gold 
standard in the diagnosis of varices. In a consensus 
meeting on methodology and therapeutic strategies in 
portal hypertension, in Italy, it was recommended that the 
size classification is as simple as possible, i.e. in 2 grades 
(small and large).5 either done by semi-quantitative 
morphological assessment or by quantitative size with a 
suggested cut-off diameter of 5 mm, with large varices 
being those greater than 5 mm. When varices are 
classified in 3 sizes—small, medium, or large—as occurs 
in most centres by a semi-quantitative morphological 
assessment (with small varices generally defined as 
minimally elevated veins above the esophageal mucosal 
surface, medium varices defined as tortuous veins 
occupying less than one-third of the esophageal lumen, 
and large varices defined as those occupying more than 
one-third of the esophageal lumen), the recommendations 
for medium-sized varices are the same as for large 
varices because this is how they were grouped in 
prophylactic trials.6 The presence of coarse irregular 
echo-texture of the liver on ultrasonography along with 
either HBsAg or anti-HCV antibody positivity for 5-10 
years was labeled as viral cirrhosis. The presence of 
mosaic-like pattern of gastric mucosa along with any of 
the three characteristics i.e.  Red Point Lesions, Cherry 
Red Spots or Black-Brown Spots, scattered diffusely over 
the gastric mucosa as seen on endoscopy, is labelled as 
portal hypertensive gastropathy.7,8 The presence of 
dilated mucosal veins (< 50% of adjacent normal veins) 
seen in a lower third of oesophagus with the help of 
endoscopy is labelled as having esophageal varices.8  
Present study was planned to find out the association of 
portal hypertensive gastropathy with esophageal varices 
in patients of cirrhosis. 
    P a t i e n t s  a n d  M e t h o d s  
This cross-sectional study was conducted at Medical Unit, 
Jinnah Hospital Lahore from 3rd September 2016 to 2nd 
January 2017. About 120 patients diagnosed with viral 
cirrhosis and duration of illness between 5 to 10 years 
undergoing screening gastric endoscopy were included in 
the study. Patients with (i) Severe acute upper GI bleed 
(>250 ml of blood in vomitus in a day. (ii) 
Hemodynamically unstable (BP < 80/60) determined by 
history and examination, (iii) Previously diagnosed with 
varices or portal hypertensive gastropathy determined by 
history and previous medical records, (iv) Patients on 
prophylactic beta-blocker or nitrates therapy determined 
by history and previous medical records (v) Any evidence 
of portal vein or splenic vein thrombosis determined by 
abdominal ultrasound (vi) Patients with a history of 
previous portosystemic shunt surgery or transjugular 
intrahepatic portosystemic shunt stent placement 
determined by history and previous medical records. (vii) 
Patients with history of Hematologic disorders such as 
Aplastic anaemia, Myelodysplastic syndrome, any other 
haematological malignancy or bleeding/coagulation 
disorder or those on anticoagulant therapy determined by 
history, (viii) Pregnancy determined by history and 
investigations. (xi) Patients on NSAID, steroids or antiviral 
therapy for more than 4 weeks determined by history and 
medical record were excluded from study. After taking 
informed consent, all patients underwent upper 
gastrointestinal tract endoscopy by consultant 
endoscopist. Findings of endoscopy (presence of portal 
hypertensive gastropathy and varices) were noted. 
Confidentiality of the data was ensured.  
Data Analysis was done by SPSS version 17.0, Numerical 
variable were summarized as mean and standard 
                            74 JIMDC  2017  74 
deviation (SD). Qualitative variables were presented in 
the form of frequency and percentages. Chi-square test 
was applied to check statistical significance. Data was 
stratified by age, gender, duration of CLD, HBsAg, Anti 
HCV and Child-Pugh Class (A, B,C) to estimate cirrhosis 
severity. Post-stratification chi-square test was applied. P-
value < 0.05 was considered as statistically significant 
R e s u l t s  
Out of 120 patients, there were 52 (43.3%) males and 68 
(56.7%) females. The mean age was 39.71+11.6 SD 
years. Minimum and maximum duration of illness was 05 
and 10 years respectively with the mean of 7.5+1.72 SD 
years. Out of total 120 study subjects, portal hypertensive 
gastropathy and esophageal varices were present in 
15(13%) and 51(43) patients respectively. Table1 showed 
frequency distribution of HBsAg, Anti-HCV and Class of 
child Pugh, A, B, and C in patients of cirrhosis. 
Association of portal hypertensive gastropathy with 
esophageal varices is shown in table 2.  
 
As shown in the table, non-significant association was 
found between portal hypertensive gastropathy and 
esophageal varices (p-value 0.364). Table 3 showed 
associations of Portal hypertensive gastropathy with 
different effect modifiers present in patients of cirrhosis. 
Table.3 Association of Portal Hypertensive 
Gastropathy with related factors in patients of 
cirrhosis   
Variables Portal Hypertensive 
Gastropathy 
p-value 
Yes 
(n=15) 
No 
(n=105) 
Age (years) 
    <40 (n=58) 
    ≥ 40 ( n=62) 
 
8 
7 
 
50 
55 
 
0.679 
Gender 
   Male (n=52) 
   Female (n=68) 
 
9 
6 
 
43 
62 
 
0.164 
Duration of illness 
(years) 
     < 8 (n=52) 
     ≥ 8 (n=68) 
 
 
9 
6 
 
 
43 
62 
 
 
0.053 
HbsAg 
     Positive (n=73) 
     Negative(n=47)  
 
10 
5 
 
63 
42 
 
0.621 
Anti-HCV 
  Positive (n=55) 
  Negative(n=65) 
 
6 
9 
 
49 
56 
 
0.628 
Child Pugh Class 
      A (n=15) 
      B (n= 57) 
      C (n= 48) 
 
0 
8 
7 
 
      15 
49 
41 
 
 
0.93 
D i s c u s s i o n  
The present study showed that frequency of portal 
hypertensive gastropathy and Esophageal varices was 
12.5% and 42.5% respectively. There was an insignificant 
association between Portal hypertensive gastropathy and 
Esophageal varices (p-value 0.364). Similarly, there was 
not a significant association between portal hypertensive 
gastropathy and other factors like age, duration of illness, 
Table 1: Frequency of different factors in patients of 
Cirrhosis  (n=120) 
Groups Frequency 
(n) 
Percentage 
(%) 
HbsAg 
       Positive 
       Negative 
 
73 
47 
 
61 
39 
Anti-HCV 
      Positive 
      Negative 
 
55 
65 
 
46 
54 
Child Pugh Class 
   A 
    B 
    C 
 
75 
57 
48 
 
13 
47 
40 
Table 2: Association of portal hypertensive 
gastropathy with esophageal varices in patients of 
cirrhosis  
Esophageal 
varices 
Portal hypertensive 
gastropathy 
p-value 
Yes (n=15) No (n=105) 
Yes (n=51) 8 43 0.364 
No   (n=69) 7 62 
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gender, HBsAg, Anti-HCV and Child Pugh class, with p 
value >0.05. 
In one of the previous studies, a strong positive 
association has been reported between the presence of 
PHG and esophageal varices (p < 0.0001). PHG was also 
found associated with the histological and biochemical 
severity of liver disease in patients with HCV and 
advanced fibrosis.9 
From another study, on univariate analysis lower platelet 
counts (117±55 vs. 167±90; p < 0.001), increased spleen 
size (14.1±2.9 cm vs. 12±2.4cm; p < 0.001) were found in 
PHG patients as compared to those without it. Similarly, 
lower platelet/spleen ratio was noted in patients with 
severe PHG (916±400 vs. 1477±899; p < 0.001). 
Furthermore, CTP score > 8 MELD score > 12 and 
platelets/spleen ratio < 900 were significantly associated 
factors with severe PHG.10 In existing research, significant 
positive correlation has been reported between 
esophageal variceal grade and PHG but not with 
Aetiology or Hypersplenism. In one of the studies the 
frequency of PHG was 79.27% compared to 12.5% in our 
study. They also observed that grade of Oesophageal 
varices had significant association with PHG, suggesting 
a common pathophysiology of both entities.12 In the same 
study it was reported that out of 217 patients, 66.4% were 
HCV positive,16.6% were HBV positive and 6.9% had co-
infection with HCV/HBV, and only 1 (0.5%) had co-
infection of HBV/HDV. Twenty-one patients (9.7%) were 
classified as having cryptogenic cirrhosis.11 
Another report mentioned the 80% prevalence of 
gastropathy and it was correlated with the duration of 
disease, presence and size of esophago gastric varices, 
and a previous history of endoscopic variceal 
sclerotherapy. They also observed that during 18 ± 8 
months of follow-up, gastropathy was stable in 29% of 
patients, deteriorated in 23%, improved in 23%, and 
fluctuated with time in 25%. The evolution of gastropathy 
with time was identical in patients with and without 
previous or current sclerotherapy. Acute bleeding from 
gastropathy occurred in 8 of 315 patients (2.5%). The 
bleeding-related mortality rate was 12.5%. Chronic 
bleeding occurred in 10.8 % patients.12 
In another study done by Fontana RJ et al, out of 1,016 
HCV patients, 37% of HALT-C patients had PHG with 
34% having mild and 3% with severe changes. The 
mucosal mosaic pattern was identified in 33%, red marks 
in 15%, and Gastric Antral Vascular Ectasia (GAVE) 
features in only 3%. Independent correlates of PHG 
included biochemical markers of liver disease severity 
(lower serum albumin, higher bilirubin), portal 
hypertension (lower platelet count), insulin resistance 
(higher glucose), and non-African American race.9  
In another study, out of 360 patients who underwent EGD 
(esophago gastro deudenoscopy) screening, 63% were 
male and 37% were females. Two hundred and eighty-
one (78%) had hepatitis C while 79 (22%) suffered from 
hepatitis B-related cirrhosis. Three hundred patients 
(83.3%) had PHG, among these 24% had severe PHG. A 
Higher proportion of esophageal varices (89.7%) was 
present among those who had PHG (p < 0.001).10 it is 
recommended that patients with cirrhosis undergo 
endoscopic screening for varices at the time of 
diagnosis.13 Since the prevalence of medium/large varices 
is approximately 15–25%, the majority of subjects 
undergoing screening EGD either do not have varices or 
have varices that do not require prophylactic therapy.14 
There is, therefore, a considerable interest in developing 
models to predict the presence of high-risk varices by 
non-endoscopic methods. Several studies have evaluated 
possible non-invasive markers of esophageal varices in 
patients with cirrhosis, such as the platelet count, 
fibrotest, spleen size, portal vein diameter, and transient 
elastography.15,16 However, the predictive accuracy of 
such non-invasive markers is still unsatisfactory, and til 
large prospective studies of non-invasive markers are 
performed, endoscopic screening is still the main means 
of assessing for the presence of esophageal varices.16 
Cost-effective analyses using Markov models have 
suggested either empiric β-blocker therapy for all patients 
with cirrhosis or screening endoscopy for patients with 
compensated cirrhosis, or universal β-blocker therapy 
without screening EGD for patients with decompensated 
cirrhosis.17,18 However a recent trial shows that β-blockers 
do not prevent the development of varices and are 
associated with significant side effects, and do not 
consider endoscopic variceal ligation as an alternative 
prophylactic therapy.18 Until prospective studies validate 
these approaches, screening EGD is still the 
recommended approach. 
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EGD also remains the main method for diagnosing 
variceal hemorrhage.13 The diagnosis of variceal 
haemorrhage is made when diagnostic endoscopy shows 
one of the following: active bleeding from varix, a “white 
nipple” overlying varix, clots overlying varix or varices with 
no other potential source of bleeding. 
C o n c l u s i o n  
Emergence of portal hypertensive gastropathy and 
Esophageal varices were noticed among viral cirrhosis 
patients with insignificant association between each other, 
Moreover, modifiers have no significant association with 
PHG. 
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